10月27日 - ** Avidity Biosciences RNA.O股价盘前大涨 43.6% 至 70.60 美元
** 如果涨势保持，股价开盘将创历史新高
** 瑞士制药商诺华NOVN.S将以约120亿美元收购美国生物技术公司 (link)
** Avidity 股东将获得每股 72 美元的现金，与上周五的收盘价 相比溢价 46
** 在交易完成之前， Avidity 将把其早期精准心脏病学项目分离出来，成立一家新公司，该公司有望上市交易
** 所有17家券商都将RNA股票评级为 "买入 "或更高；根据伦敦证券交易所的数据，中位价为65美元
** 与纳斯达克生物技术指数.NBI20.3%的涨幅相比，RNA今年以来上涨了69%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.